Inductionless or Limited Shock Testing Is Possible in Most Patients With Implantable Cardioverter- Defibrillators/Cardiac Resynchronization Therapy Defibrillators
Authors:
- John D. DayJDJohn D. Day
- Rahul N. DoshiRDRahul N. Doshi
- Peter BelottPBPeter Belott
- Ulrika Birgersdotter-GreenUBUlrika Birgersdotter-Green
- Mahnaz BehboodikhahMBMahnaz Behboodikhah
- Peter OttPOPeter Ott
- Kathryn A. GlatterKGKathryn A. Glatter
- Serge TobiasSTSerge Tobias
- Howard FruminHFHoward Frumin
- Byron K. LeeBLByron K. Lee
- John MerillatJMJohn Merillat
- Isaac WienerIWIsaac Wiener
- 8 May 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (18) , 2382-2389
Abstract
Background— Implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators have relied on multiple ventricular fibrillation (VF) induction/defibrillation tests at implantation to ensure that the device can reliably sense, detect, and convert VF. The ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations) is the first large, multicenter, prospective trial comparing vulnerability safety margin testing versus defibrillation safety margin testing with a single VF induction/defibrillation. Methods and Results— A total of 426 patients receiving an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator underwent vulnerability safety margin or defibrillation safety margin screening at 14 J in a randomized order. After this, patients underwent confirmatory testing, which required 2 VF conversions without failure at ≤21 J. Patients who passed their first 14-J and confirmatory tests, irrespective of the results of their second 14-J test, had their devices programmed to a 21-J shock for ventricular tachycardia (VT) or VF ≥200 bpm and were followed up for 1 year. Of 420 patients who underwent 14-J vulnerability safety margin screening, 322 (76.7%) passed. Of these, 317 (98.4%) also passed 21-J confirmatory tests. Of 416 patients who underwent 14-J defibrillation safety margin screening, 343 (82.5%) passed, and 338 (98.5%) also passed 21-J confirmatory tests. Most clinical VT/VF episodes (32 of 37, or 86%) were terminated by the first shock, with no difference in first shock success. In all observed cases in which the first shock was unsuccessful, subsequent shocks terminated VT/VF without complication. Conclusions— Although spontaneous episodes of fast VT/VF were limited, there was no difference in the odds of first shock efficacy between groups. Screening with vulnerability safety margin or defibrillation safety margin may allow for inductionless or limited shock testing in most patients.Keywords
This publication has 20 references indexed in Scilit:
- One conversion of ventricular fibrillation is adequate for implantable cardioverter-defibrillator implant: An analysis from the Low Energy Safety Study (LESS)Heart Rhythm, 2005
- Is defibrillation testing required for defibrillator implantation?JACC, 2004
- Acute Pulmonary Edema Secondary to Myocardial Damage After Electrical CardioversionPacing and Clinical Electrophysiology, 2003
- Successful Implantation of Cardiac Defibrillators Without Induction of Ventricular Fibrillation Using Upper Limit of Vulnerability TestingJournal of Interventional Cardiac Electrophysiology, 2003
- Analysis of Troponin I Levels After Spontaneous Implantable Cardioverter Defibrillator ShocksJournal of Cardiovascular Electrophysiology, 2002
- Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: results of the prospective, randomized, multicenter low-energy endotak trialThe American Journal of Cardiology, 1999
- Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillatorsJACC, 1996
- Defibrillation Threshold: Clinical Utility and Therapeutic ImplicationsPacing and Clinical Electrophysiology, 1992
- Clinical Evaluation of the Safety of Repetitive Intraoperative Defibrillation Threshold TestingPacing and Clinical Electrophysiology, 1992
- Defibrillation threshold testing: Necessary but evil?American Heart Journal, 1989